CD358 / DR6

CD Markers
CD358 / DR6

Author: Nat Pernick, M.D. (see Authors page)

Revised: 8 December 2015, last major update November 2014

Copyright: (c) 2003-2015, PathologyOutlines.com, Inc.

PubMed Search: DR6

Table of Contents

Cite this page: CD358 / DR6. PathologyOutlines.com website. http://www.pathologyoutlines.com/topic/cdmarkerscd358.html. Accessed July 12th, 2017.

Definition / general

Also called TNFRSF21, death receptor 6
Member of tumor necrosis factor receptor superfamily
First characterized at Ninth HLDA Workshop (HLDA9) (Immunol Lett 2011;134:104)
Different from HLA-DR6 (Int J Rheum Dis 2014;17:268) and protein product of direct repeat 6 (associated with HHV6A and HHV6B, J Virol 2010;84:2648, Virology 2014;452:254)

Pathophysiology

Induces apoptosis when overexpressed (FEBS Lett 1998;431:351)
Highly expressed in brain
- Induces axon pruning and neuron death (J Neurodev Disord 2013;5:10); binds to amyloid precursor protein (APP); may be involved in development of Alzheimer's disease (J Mol Biol 2011;409:189, Proteins 2011;79:1376, Nature 2009;457:981)
- Regulates brain vascular developmentDev Cell 2012;22:403
May be involved in pathogenesis of endometriosis (Am J Reprod Immunol 2013;70:485)

Uses by pathologists

No specific uses as this time

Microscopic (histologic) images

Images hosted on other servers:

DR6 immunoreactivity in control and Down syndrome adult hippocampus

With caspase 6

DR6 at different gestational ages
(normal and Down syndrome)

Positive staining - disease

Serum DR6 protein levels elevated in ovarian carcinoma (Cancer Biol Ther 2011;12:169); also adult sarcoma, particularly synovial sarcoma (PLoS One 2012;7:e36525)

Negative staining

Serum DR6 levels not elevated in uterine carcinosarcoma, bladder, liver or pancreatic cancer